ARTICLE | Discovery & Translation

Acidifying lysosomes to treat NAFLD; Sherlock’s nucleic acid assay and more

BioCentury’s roundup of translational news

May 17, 2023 10:49 PM UTC

Scientists from  Boston University and University of California Los Angeles, reported in Nature Communications nanoparticles that improved insulin sensitivity and reversed liver steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). The nanoparticles, composed of fluorinated polyesters that only become activated in the acidic environment of dysfunctional lysosomes, further acidifies and enhances the function of the lysosomes.

Two of the authors, Orian Shirihai and Mark Grinstaff, are co-founders of Enspire Bio Inc. and  Capacity Bio Inc., which are testing therapeutic applications of the acidic nanoparticles...